{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:53:31Z","timestamp":1781639611937,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Lorazepam is frequently used in pancreatic cancer patients receiving chemotherapy for its antiemetic properties and to mitigate psychological distress. However, N-unsubstituted benzodiazepines like lorazepam may adversely impact pancreatic cancer progression by stimulating fibrosis and inflammatory signaling. This study aimed to retrospectively compare the survival rates of pancreatic cancer patients exposed to lorazepam with those who were not exposed to real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were retrospectively reviewed from patients aged\u2009\u2265\u200918\u00a0years with pathologically confirmed pancreatic cancer who received palliative chemotherapy at Seoul National University Hospital between January 2011 and January 2023. Patients were dichotomized based on lorazepam administration: those who received\u2009\u2265\u200915\u00a0mg (equivalent to\u2009\u2265\u20091 tablet daily for 30\u00a0days) were classified as the high-dose group, and those who received\u2009&lt;\u200915\u00a0mg were classified as the low-dose group. The relationship between lorazepam exposure and progression-free survival (PFS), as well as overall survival (OS), was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among pancreatic cancer patients undergoing palliative chemotherapy, PFS was worse in the high-dose lorazepam group compared to the low-dose group [median, 6\u00a0months (5\u20137) vs. 8\u00a0months (7\u20139), p\u2009=\u20090.025]. However, there was no difference in OS between the two groups [median, 11\u00a0months (10\u201312) vs. 12\u00a0months (11\u201313), p\u2009=\u20090.465].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher cumulative lorazepam exposure was associated with shorter progression-free survival in Asian patients with pancreatic cancer treated with palliative chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01429-7","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:42:19Z","timestamp":1772440939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"57","author":[{"given":"Tae Seung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Kon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-3280","authenticated-orcid":false,"given":"Woo Hyun","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1429_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"1429_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36:2129884. https:\/\/doi.org\/10.1080\/08941939.2022.2129884.","journal-title":"J Invest Surg"},{"key":"1429_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"key":"1429_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1.","journal-title":"Lancet"},{"key":"1429_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"1429_CR6","doi-asserted-by":"publisher","first-page":"e2133388","DOI":"10.1001\/jamanetworkopen.2021.33388","volume":"4","author":"MJ Raphael","year":"2021","unstructured":"Raphael MJ, Raskin W, Habbous S, et al. The association of drug-funding reimbursement with survival outcomes and use of new systemic therapies among patients with advanced pancreatic cancer. JAMA Netw Open. 2021;4:e2133388. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33388.","journal-title":"JAMA Netw Open"},{"key":"1429_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"key":"1429_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12602-024-10437-7","author":"TS Lee","year":"2024","unstructured":"Lee TS. Are probiotics beneficial or harmful for pancreatic cancer outcomes? Probiotics & Antimicro Prot. 2024. https:\/\/doi.org\/10.1007\/s12602-024-10437-7.","journal-title":"Probiotics & Antimicro Prot"},{"key":"1429_CR9","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.18632\/oncotarget.4183","volume":"6","author":"T Golan","year":"2015","unstructured":"Golan T, Khvalevsky EZ, Hubert A, et al. Rnai therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560\u201370. https:\/\/doi.org\/10.18632\/oncotarget.4183.","journal-title":"Oncotarget"},{"key":"1429_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194708","volume":"15","author":"TS Lee","year":"2023","unstructured":"Lee TS, Kim JY, Lee MH, et al. Savolitinib: a promising targeting agent for cancer. Cancers. 2023;15:4708.","journal-title":"Cancers"},{"key":"1429_CR11","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.Ccr-23-0547","volume":"29","author":"AC Cornwell","year":"2023","unstructured":"Cornwell AC, Tisdale AA, Venkat S, et al. Lorazepam stimulates IL6 production and is associated with poor survival outcomes in pancreatic cancer. Clin Cancer Res. 2023;29:3793\u2013812. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0547.","journal-title":"Clin Cancer Res"},{"key":"1429_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3322\/CA.2008.0003","volume":"58","author":"PB Jacobsen","year":"2008","unstructured":"Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin. 2008;58:214\u201330. https:\/\/doi.org\/10.3322\/CA.2008.0003.","journal-title":"CA Cancer J Clin"},{"key":"1429_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/00130404-200609000-00008","volume":"12","author":"K Miller","year":"2006","unstructured":"Miller K, Massie MJ. Depression and anxiety. Cancer J. 2006;12:388\u201397. https:\/\/doi.org\/10.1097\/00130404-200609000-00008.","journal-title":"Cancer J"},{"key":"1429_CR14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1054\/bjoc.2000.1405","volume":"83","author":"DP Stark","year":"2000","unstructured":"Stark DP, House A. Anxiety in cancer patients. Br J Cancer. 2000;83:1261\u20137. https:\/\/doi.org\/10.1054\/bjoc.2000.1405.","journal-title":"Br J Cancer"},{"key":"1429_CR15","unstructured":"PD JE. Recent updates in the management of chemotherapy-induced nausea and vomiting. Asian J Pharm Clin Res. 2013;6(Suppl 1):5\u201310. https:\/\/journals.innovareacademics.in\/index.php\/ajpcr\/article\/view\/323"},{"key":"1429_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2024.08.027","author":"DI Tsilimigras","year":"2024","unstructured":"Tsilimigras DI, Woldesenbet S, Chatzipanagiotou OP, et al. Long-term lorazepam use may be associated with worse long-term outcomes among patients with pancreatic adenocarcinoma. Surgery. 2024. https:\/\/doi.org\/10.1016\/j.surg.2024.08.027.","journal-title":"Surgery"},{"key":"1429_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tips.2020.10.001","volume":"41","author":"AC Cornwell","year":"2020","unstructured":"Cornwell AC, Feigin ME. Unintended effects of GPCR-targeted drugs on the cancer phenotype. Trends Pharmacol Sci. 2020;41:1006\u201322. https:\/\/doi.org\/10.1016\/j.tips.2020.10.001.","journal-title":"Trends Pharmacol Sci"},{"key":"1429_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1200\/JCO.1984.2.6.691","volume":"2","author":"JF Bishop","year":"1984","unstructured":"Bishop JF, Olver IN, Wolf MM, et al. Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. J Clin Oncol. 1984;2:691\u20135. https:\/\/doi.org\/10.1200\/JCO.1984.2.6.691.","journal-title":"J Clin Oncol"},{"key":"1429_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/jpp.JPP_54_17","volume":"8","author":"A James","year":"2017","unstructured":"James A, Nair MM, Abraham DS, et al. Effect of lorazepam in reducing psychological distress and anticipatory nausea and vomiting in patients undergoing chemotherapy. J Pharmacol Pharmacother. 2017;8:112. https:\/\/doi.org\/10.4103\/jpp.JPP_54_17.","journal-title":"J Pharmacol Pharmacother"},{"key":"1429_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","volume":"41","author":"HG Xie","year":"2001","unstructured":"Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815\u201350. https:\/\/doi.org\/10.1146\/annurev.pharmtox.41.1.815.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1429_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamaoncol.2016.2616","volume":"3","author":"DK Check","year":"2017","unstructured":"Check DK, Basch EM. Appropriate use of antiemetics to prevent chemotherapy-induced nausea and vomiting. JAMA Oncol. 2017;3:307\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2616.","journal-title":"JAMA Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01429-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01429-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01429-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:08:47Z","timestamp":1781636927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01429-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01429-7","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Seoul National University Hospital (Date: 2023.11.02\/No. H-2011\u2013051-1171).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Seoul National University Hospital, its affiliated institutions, or the funding agencies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"55"}}